Description

Description

Diajard-M XR 10/1000mg is a prescription medicine manufactured by Highnoon Laboratories, combining Empagliflozin and Metformin in an extended-release tablet form. This fixed-dose combination brings together two complementary approaches to blood sugar management, with the Metformin component formulated to release gradually over time rather than all at once. Empagliflozin belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, working by limiting glucose reabsorption in the kidneys and encouraging its excretion through urine. In this strength, Empagliflozin sits at a moderate level within the Diajard-M XR range, paired with the higher extended-release Metformin dose, making it typically suited for patients whose treatment plan calls for a mid-range Empagliflozin dose alongside stronger Metformin support. Metformin works mainly by reducing glucose production in the liver while improving the body’s response to insulin, with its gradual release profile intended to help reduce the gastrointestinal discomfort that can accompany immediate-release Metformin, even at this higher strength. Each pack of Diajard-M XR 10/1000mg contains 14 tablets, produced under the quality standards maintained by Highnoon Laboratories.

Ingredients

Diajard-M XR 10/1000mg contains two active ingredients: Empagliflozin at a strength of 10 milligrams and Metformin Hydrochloride, in extended-release form, at a strength of 1000 milligrams per tablet. The formulation also includes inactive excipients such as extended-release matrix-forming agents, binding materials, and film-coating components, which work together to control the gradual release of Metformin and support the tablet’s structural integrity. These excipients carry no therapeutic effect on their own but are essential to the tablet’s release mechanism and overall stability.

Dosage Form

Diajard-M XR 10/1000mg is available as an oral extended-release film-coated tablet. Each pack contains 14 tablets, providing a supply suited to a once-daily combination treatment schedule as directed by a physician. Owing to its extended-release design, the tablet should be swallowed whole and must not be crushed, split, or chewed, as this could interfere with the controlled release mechanism.

Uses

Diajard-M XR 10/1000mg is used to help improve blood sugar control in adults with type 2 diabetes mellitus, particularly where a physician determines that a moderate Empagliflozin dose alongside a higher extended-release Metformin strength is appropriate for the patient’s individual treatment needs. It is generally used alongside dietary changes and regular physical activity as part of a broader diabetes management plan. This medicine is not intended for individuals with type 1 diabetes or for the management of diabetic ketoacidosis. The suitability of this specific strength for any individual patient should always be confirmed through proper medical assessment.

How to Use

Diajard-M XR 10/1000mg should be taken exactly as directed by a prescribing physician, typically once daily with the evening meal, which may help support tolerability and the intended extended-release action, particularly given the higher Metformin content. The tablet must be swallowed whole with a glass of water and should never be crushed, split, or chewed, as doing so could disrupt the extended-release formulation and alter how the medicine is absorbed. Patients should continue to follow any dietary and lifestyle recommendations provided by their doctor and must never modify the dosage without medical advice. Regular monitoring of blood sugar levels and kidney function is typically recommended throughout treatment.

Side Effects

Diajard-M XR 10/1000mg may cause side effects in some individuals, although not everyone will experience them. Commonly reported effects include gastrointestinal symptoms such as mild nausea, diarrhea, or stomach discomfort, which may be more noticeable at this higher Metformin strength despite the extended-release formulation, particularly when treatment is first started. Effects associated with the Empagliflozin component, such as urinary tract infections, genital yeast infections, and increased urination, may also occur. Some patients may notice mild dizziness or symptoms related to dehydration. A rare but serious risk linked to Metformin-containing medicines is lactic acidosis, which can present as unusual muscle pain, difficulty breathing, abdominal discomfort, or unexplained fatigue, requiring immediate medical attention if suspected. Patients with kidney or liver concerns, a history of heavy alcohol use, or those undergoing procedures involving contrast dye should inform their doctor before starting this medicine.

Pregnancy & Breastfeeding

The use of Diajard-M XR 10/1000mg during pregnancy or breastfeeding should only occur under the specific direction of a qualified healthcare provider, as its suitability depends on individual clinical circumstances. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with their doctor before starting or continuing this combination medicine.

Storage Instructions

Diajard-M XR 10/1000mg tablets should be stored in a cool, dry place away from direct sunlight and excess humidity, at the room temperature indicated on the packaging. Tablets should remain in their original blister pack until they are ready to be used, helping protect them from moisture and light exposure. Keep out of reach of children and pets, and avoid storage in areas with fluctuating temperatures such as bathrooms or vehicles.

FAQS

Q: Where does Diajard-M XR 10/1000mg fit within the Diajard-M XR range?
It sits at a moderate Empagliflozin strength paired with the higher extended-release Metformin dose, positioning it between the lower and highest combination strengths.

Q: Can Diajard-M XR 10/1000mg tablets be split or crushed?
No, the tablet should always be swallowed whole, as splitting or crushing can interfere with its extended-release mechanism.

Q: Should Diajard-M XR 10/1000mg be taken at a specific time of day?
It is generally taken once daily with the evening meal, though the exact timing should follow the prescribing doctor’s instructions.

Q: Is stomach upset less likely with the extended-release formulation?
Many patients experience fewer gastrointestinal symptoms with extended-release Metformin compared to immediate-release forms, though individual responses can still vary, especially at higher strengths.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.